Creating a vaccine to stimulate the immune system against HIV
Leveraging membrane Env liposome vaccine design to elicit multi-target cross-neutralization of HIV
['FUNDING_R01'] · SCRIPPS RESEARCH INSTITUTE, THE · NIH-11057572
This study is testing a new vaccine that aims to boost the immune system's ability to fight HIV by helping it produce special antibodies, and it's designed for people interested in better ways to prevent HIV infection.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SCRIPPS RESEARCH INSTITUTE, THE (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11057572 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel vaccine designed to activate specific immune cells that can produce broadly neutralizing antibodies (bnAbs) against HIV. The approach utilizes a unique liposome platform that targets germline precursors of these antibodies, aiming to enhance the immune response in animal models, particularly rhesus macaques. By employing a strategy known as Germline Targeting, the researchers hope to effectively prime the immune system to recognize and combat HIV more efficiently. The study will assess the vaccine's ability to elicit strong immune responses that could lead to effective protection against HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at high risk for HIV infection or those who are HIV-negative but may benefit from preventive measures.
Not a fit: Patients who are already HIV-positive or those with compromised immune systems may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking HIV vaccine that provides long-lasting immunity and protection against the virus.
How similar studies have performed: Previous research has shown promise in similar approaches to vaccine development, particularly in eliciting immune responses against HIV, but this specific method is relatively novel.
Where this research is happening
LA JOLLA, UNITED STATES
- SCRIPPS RESEARCH INSTITUTE, THE — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZWICK, MICHAEL B — SCRIPPS RESEARCH INSTITUTE, THE
- Study coordinator: ZWICK, MICHAEL B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus